AngioDynamics Comments on Patent Infringement Lawsuit Related to VenaCure Laser ProductsQUEENSBURY, N.Y.--(BUSINESS WIRE)--Oct. 7, 2005--AngioDynamics, Inc. (Nasdaq: ANGO) today announced the Company has become aware that it has been added to a patent infringement suit originally filed by VNUS Medical Technologies, Inc. in the United States District Court for the Northern District of California against Diomed, Inc., by the filing of an amended complaint alleging infringement by the AngioDynamic's VenaCure^™ products. VenaCure is a laser system used for the treatment of severe varicose veins.

The suit involves patent numbers 6,258,084; 6,638,273; 6,752,803; and 6,769,433, all of which relates to endovascular treatment of varicose veins. AngioDynamics has not yet been served with the complaint.

"The Company has analyzed the VNUS patents, and has consulted with its outside counsel on this matter," said Eamonn P. Hobbs, president and chief executive officer of AngioDynamics. "We believe that we have no liability under the asserted patents as a result of our manufacture and sale of our VenaCure products, and we intend to vigorously defend our position."

About VenaCure

The VenaCure endovascular laser venous system is a patient friendly, minimally invasive alternative for the treatment of severe varicose veins. The VenaCure procedure, which lasts about 45 minutes, offers patients an effective out-patient alternative to surgical ligation and vein stripping. The Company markets and sells the VenaCure laser system throughout the United States.

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.
William Appling, 800-772-6446 x130
www.angiodynamics.com


or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com


or
Bruce Voss, 310-691-7100
bvoss@lhai.com



SOURCE: AngioDynamics, Inc.